跳至主要内容
临床试验/NCT00562211
NCT00562211已完成1 期

A Single-blind, Randomized, Controlled Trial to Assess the Efficacy of a New Topical Anesthetic in Reducing Pain Associated With Venipuncture in Children.

Rambam Health Care Campus1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
40
试验地点
1
主要终点
Self report assessment of pain (using the Visual Analog Scale)

研究概览

简要总结

A new topical anesthetic which contains 5% lidocaine and a disinfection ingredient has been developed and is tested in this study (LidoDyn).

The study examines the efficacy of LidoDyn by comparing it with an already proven anesthetic agent (EMLA crème).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
12 Years 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Previously healthy children of whom venipuncture is needed to be performed.

排除标准

  • History of allergic reaction to any local anesthetic.
  • History of chronic disease
  • Patient's condition requires urgent treatment (e.g. severe dehydration, shock)
  • Active local skin infection or skin pathologic condition at the antecubital fossa
  • Tattoo, surgical scar or skin condition that might interfere with skin sight assessment.
  • Patient undergone venipuncture at the antecubital fossa within the pror two weeks.
  • Uncooperative or exceptionally anxious patient.

研究组 & 干预措施

1

Experimental

干预措施: LidoDyn (Drug)

2

Active Comparator

干预措施: EMLA creme (Drug)

结局指标

主要结局

Self report assessment of pain (using the Visual Analog Scale)

时间窗: 60 Min+ 5-10 Min

次要结局

  • Medical staff observational assessment of pain (in a scale of 0 to 10)(60 Min + 5-10 Min)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

i_shavit

Pediatric Emergency Department director

Rambam Health Care Campus

研究点 (1)

Loading locations...

相似试验

已完成
不适用
A clinical trial to evaluate the short-term efficacy of 650nm wavelength of Ellise on non specific chronic low back paiDiseases of the musculoskeletal system and connective tissue
KCT0007167WONTECH106
进行中(未招募)
1 期
Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy SubjectsHealthySafety and Tolerability
NCT05997641Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)96
Unknown
2 期
A clinical Study to assess the Efficacy and Safety of Ursodiol Injection in covid-19 patients
CTRI/2021/11/038307Shilpa Medicare Limited16
进行中(未招募)
不适用
A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µg in Healthy Adolescents Aged 11 to 18 YearsThe test is a vaccine. The subjects are healthy adolescents.MedDRA version: 14.1Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestations
EUCTR2008-007789-51-PLPfizer Inc715
进行中(未招募)
不适用
A clinical study to test the safety and immune response of a vaccine against a bacteria causing meningitis B at doses of 60 µg, 120 µg, and 200 µg in healthy adolescents aged 11 to 18 YearsPrevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.MedDRA version: 17.1Level: LLTClassification code 10004049Term: Bacterial meningitisSystem Organ Class: 100000004862
EUCTR2008-007789-51-Outside-EU/EEAWyeth Research Division of Wyeth Pharmaceuticals Inc.539